Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas.
We have examined the impact of methylprednisolone acetate (MPA) on survival of F344 rats that were bearing avian sarcoma virus (ASV)-induced gliomas and that were treated optimally with radiotherapy. Toxicity of MPA (dose range of 0.2-5.0 mg/kg X 7 over 3 weeks) was first established in non-tumor bearing rats as assessed by their relative failure to gain weight. Doses of 2.0 or 5.0 mg/kg X 7 caused animals to be 21.8 or 43.9%, respectively, underweight compared with vehicle controls. In rats bearing ASV-induced gliomas, treatment with 3,000 cGY (nine fractions over a 3-week period) alone or with 0.2 or 1.0 mg MPA/kg (X 6 during the 3-week radiotherapy course) produced a significantly prolonged survival compared with that of untreated, tumor bearing rats. However, MPA did not enhance survival when given concurrently with radiotherapy; indeed, at the higher of these two doses, median survival of tumor-bearers was slightly less than with radiotherapy alone. This trend towards interference with the beneficial effects of radiotherapy was more pronounced with the highest dose of MPA studied, 5.0 mg/kg body weight X 6. These animals had a median survival time that was significantly less than that of tumor-bearers receiving radiotherapy alone, but not significantly different from untreated rats with gliomas. The possible significance of these observations is discussed.
D000818:Animals; D001717:Birds; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005910:Glioma / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D001357:Sarcoma, Avian / Q000628:therapy
D008775:Methylprednisolone